Autologous peripheral blood-derived CD34+ cells

Generic Name: Autologous peripheral blood-derived CD34+ cells

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Background: Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Special delivery nanoparticle can program stem cells while inside the body

James Dahlman's team developed a nanoparticle (LNP67) that can program stem cells inside the body, simplifying treatments for blood disorders and genetic diseases by avoiding invasive procedures and chemotherapy.

clinicaltrialsarena.com

4 months ago

CellProthera inches closer to Phase III trial for heart attack cell therapy

CellProthera's positive pre-IND meeting with FDA paves way for Phase III trial of ProtheraCytes, a cell therapy for myocardial infarction. The trial, with a two-year follow-up, aims to prevent subsequent heart diseases. The company plans to pursue RMAT designation for expedited development and review.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy